NeurologyLive® Friday 5 — September 16, 2022

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Peer Exchange: Unmet Needs in Multiple Sclerosis Clinical Trial Design

Ahmed Obeidat, MD, PhD; Benjamin Greenberg, MD; and Hesham Abboud, MD, comment on the need for more inclusive clinical trial patient enrollment criteria, highlighting underserved patient populations in episode 2 of the NeurologyLive^® Peer Exchange series, "Multiple Sclerosis Treatments on the Horizon: BTK Inhibitors."

2: International Parkinson and Movement Disorders Society Congress

Following along with NeurologyLive^®'s coverage of the International Parkinson and Movement Disorder Society (MDS) Annual Meeting, which gathers thousands of clinicians, researchers, trainees, and industry supporters to discuss the diagnosis and treatment of movement disorders on an annual basis.

3: NeuroVoices: Lynn Bekris, PhD, on Future Research for sTREM2, GFAP, and Immunotherapies in Alzheimer Disease

In the latest edition of our in-depth Q&A series, the molecular biologist at the Cleveland Clinic Lerner Research Institute discussed the unanswered questions regarding biomarkers sTREM2 and GFAP, and the role they play in Alzheimer pathology.

4: NurOwn Treatment Shows Positive Results in Phase 2 Study of Progressive Multiple Sclerosis

Treatment with NurOwn resulted in response on several secondary outcomes, including timed 25-foot walk, 12-item multiple sclerosis walking scale, and low contrast letter acuity, among others.

5: Transitioning Sleep Schedules for School in Pediatric Patients: Carol Rosen, MD

The professor of pediatrics at Case Western University discussed the complexities and negative effects for children drastically change their sleep schedules as school begins.

—————————————————